Navigation Links
Researchers Uncover Critical Player in Cell Communication

I outside the cell nucleus led us to suspect that this protein must be doing more than regulate gene expression,” says Desiderio.

Under normal conditions, calcium does not flow freely into and out of cells until a demand for it - such as a muscle contraction or nerve function -- triggers cells to take up the free floating element from their surroundings. Cells store calcium until still other signals occur to release it again.

“The finding was stunning to us because calcium is one of the most important messengers in cells,” says Desiderio, “and both it and TFII-I are in every cell. That affirmed our suspicion that TFII-I could be doing something important with calcium signaling.”

In one experiment, the Hopkins team knocked down the amount of TFII-I in lab-grown cells and looked for changes in calcium flow under a high-power microscope using a dye that glows when it comes in contact with calcium. A camera attached to the microscope recorded the brightness of the glow and fed that measure into a computer that calculates the amount of calcium.

Knocking down TFII-I and separately assaulting the cells with chemicals caused the cells to take up more calcium than usual.

The researchers realized that when they depleted the cells of TFII-I, the cell responded by installing more calcium channels in their surfaces that allow calcium and only calcium to enter the cell. “We think TFII-I must control calcium entry into the cell by somehow limiting the number of calcium channels at the cell’s surface,” says Desiderio.

“There’s good evidence suggesting that the frequency and intensity of this ebb and flow of calcium can determine a cell’s response to external cues,” says Desiderio. “TFII-I may be a universal player in communication between cells, in the brain, the immune system and elsewhere.”
Source-Newswise
SRM
'"/>




Page: 1 2

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. Researchers discover receptor cells that can cause epilepsy
8. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
9. Researchers reversed the process of memory loss
10. Researchers Identify Key Gene That May Help Brain Treatment
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
(Date:5/16/2008)... - Gefitinib, the once-promising drug formerly app...also known as Iressa, enhanced the effectiveness o...ypes of metastatic breast cancer, according to a P...niversity of Texas M. D. Anderson Cancer Center. ,... first positive study for Iressa in breast cancer,...
(Date:5/16/2008)...ounces appointment of Nomura Code Securities Limit... broker, NEW YORK, May 16 /PRNewswire-FirstCall/ ...estments, Inc. (Amex: MGT ) (the "Company"), and ...Aided Detection (CAD) and,image analysis software ...,of disease, today announced the appointment of NM...
(Date:5/16/2008)...it Portland to Rally Residents to Eat Right, Move ...ts, PORTLAND, Ore., May 16 /PRNewswire/ -- The la...ifferent fad diets -- which seem to go in and out,...ong-term success has been,slim. Two out of three A...ents -- remain overweight or obese., A new campai...
(Date:5/16/2008)...of two proteins in mammalian embryos prevents the ...earchers at the Medical College of Wisconsin, Milw...the May 15 issue of Developmental Biology, was led...gy, neurobiology and anatomy at the Medical Colleg...ly identified the factors responsible for the onse...
Breaking Medicine News(10 mins):Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 2Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 3Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 3Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts 2
...ith a common form of brewer's yeast, University of...l functions of a key protein// that allow it to ac...determines gene activity and that, when malfunctio...ous neurological disorders. The work, published in...
... half months after his sexual organ was completely...o lead a normal life again after a Delhi hospital/...e unmarried man from Uttar Pradesh underwent a sev... Sir Ganga Rama Hospital (SGRH), a leading private...
...scientists at Johns Hopkins are making mathematica...ays to perform a surgery.// Surgical tasks such as...illustrated in this model. The team's long-term g...evaluating a surgeon's work and to help doctors im...
...n parliamentarians will attend a two-day conferenc...e's elected representatives in combating the disea...a worldwide network of individual parliamentarians... assembly of Punjab (Pakistan), Pakistan National ...
Other Medicine News:Health News:From a Lowly Yeast, Researchers Divine a Clue to Human Disease 2Health News:Delhi Hospital Reattaches Amputated Penis 2Health News:Robotic Model To Teach Surgical Skills 2Health News:Robotic Model To Teach Surgical Skills 3
(Date:5/15/2008)... BASEL, Switzerland, May 15 /- Patie...orld,s most common cancers, can expect,further tre...Herceptin(R),(trastuzumab) following new data that...f Clinical Oncology (ASCO) annual meeting in Chica...s will attend the meeting which,is the premier eve...
(Date:5/15/2008)...Phase II Data Presented at ASCO Showed Acceptable ...ce of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N...emotherapeutic agent eribulin mesylate (E7389) dem...ion of women with locally advanced or metastatic,b...er Phase II clinical,trial. The study also suggest...
(Date:5/15/2008)...ood pressure reductions demonstrated in Blacks, Hi...etes and Obese Individuals, PARSIPPANY, N.J., May...d today that data presented at the American Societ...c Meeting (ASH 2008) in New,Orleans demonstrated t...pine and olmesartan medoxomil) safely and effectiv...
(Date:5/15/2008)... APPENZELL, Switzerland, May 15 /- E...es Food and Drug Administration (FDA) has,granted ...ment of pulmonary,arterial hypertension (PAH). Ter...ivotal Phase II trial in Europe., "The FDA,s gran...encourages and strengthens our development program...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Healthcare Crisis Brought to Life in New TV Show 11337 1Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 1Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 2Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 3CorVel to Present at UBS Global Healthcare Services Conference 11332 1CorVel to Present at UBS Global Healthcare Services Conference 11332 2Gene Plays Jekyll and Hyde Role in Deadly Brain Cancer 11331 1
....5 and 40/25 mg/day and Amlodipine +,Benazepril 5/...of,Hypertension Twenty-Second Annual Scientific Me... -- New data,presented today at the American Socie...ic Meeting (ASH 2007) in Chicago,demonstrated that...n medoxomil/hydrochlorothiazide) was associated wi...
...-May 21, 2007 - Medical,professionals seeking to t...cquired gram-negative pneumonia may have a new wea...ct candidate being,developed by Nektar Therapeutic...rial evaluating the use of,NKTR-061 (Inhaled Amika...h hospital-acquired gram-negative pneumonia were,p...
Other Medicine Technology:Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
... value in high performance electronic pipetting!, ...design reduce hand fatigue and strain , Stress-fre...r coding for easy volume identification , Accepts ...lton AdvanTip Low Retention and AdvanTip Precision...
The Finnpipette BioControl multichannel has the same innovative features as the single channel model.The same universal handle fits all seven multichannel and five single channel tip cone modules. Bo
...s ideal for all liquid handling applications in th...cally-placed operating buttons, and various dispen...erse pipetting and diluting make this a lab favori... a manual pipette without any adverse effects on t...
...vus is so user-friendly that you'll learn how to u...stantly familiar menu and simple button layout, yo...quickly and easily. The large, clear display is ea...ns. The easily accessible two level menu offers t...
Medicine Products: